Sobi to sell another rare disease drug in Saudi Arabia

The Saudi Food & Drug Authority (SFDA) has approved Swedish Orphan Biovitrum’s (Sobi) Elocta (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion protein with an extended half-life, for the treatment of haemophilia A. 

Elocta is the first extended half-life and recombinant factor VIII Fc fusion protein therapy approved for the treatment of haemophilia A in Saudi Arabia, the company said in its press release on Thursday.

 “The approval of Elocta in Saudi Arabia is an important development for the haemophilia community in the Middle East and will enable physicians to offer their patients a wider range of treatment options.” says Ahmad Abu-Dahab, Regional Director Middle East, & Turkey.

“We will now focus on ensuring access to Elocta for people living with haemophilia A across other Middle Eastern states.” says Ebrahim Al-Hagiri, Regulatory & Patient Access Manager Middle East & Turkey .

Elocta is indicated for both on-demand and prophylaxis treatment of people with haemophilia A of all ages, the company noted.

To remind, Sobi announced on Wednesday that SFDA has approved its hereditary tyrosinemia drug.